Microglia maintain homeostasis in the central nervous system through phagocytic clearance of protein aggregates and cellular debris. This function deteriorates during ageing and neurodegenerative disease, concomitant with cognitive decline. However, the mechanisms of impaired microglial homeostatic function and the cognitive effects of restoring this function remain unknown. We combined CRISPR-Cas9 knockout screens with RNA sequencing analysis to discover age-related genetic modifiers of microglial phagocytosis. These screens identified CD22, a canonical B cell receptor, as a negative regulator of phagocytosis that is upregulated on aged microglia. CD22 mediates the anti-phagocytic effect of α2,6-linked sialic acid, and inhibition of CD22 promotes the clearance of myelin debris, amyloid-β oligomers and α-synuclein fibrils in vivo. Long-term central nervous system delivery of an antibody that blocks CD22 function reprograms microglia towards a homeostatic transcriptional state and improves cognitive function in aged mice. These findings elucidate a mechanism of age-related microglial impairment and a strategy to restore homeostasis in the ageing brain.
. During this period, microglia peruse the brain parenchyma with ramified processes to sense perturbations 3 and respond with specialized compensatory functions. One of the core microglial functions necessary for homeostasis in the central nervous system (CNS) is the recognition, engulfment and degradation of extracellular material via phagocytosis 4 . Whereas microglial phagocytosis is crucial throughout an organism's lifespan, the targets of engulfment change depending on age. For example, complement-mediated synaptic pruning is essential for developmental circuit refinement 5, 6 , yet inappropriate activation of this pathway in neurodegenerative diseases may contribute to deleterious synapse elimination 7, 8 . During normal ageing and age-related disease, microglia encounter distinct perturbations in the CNS, including abundant myelin debris 9 and protein aggregates. A complex system of extrinsic and intrinsic inhibitory molecules normally regulates microglial phagocytosis to enable efficient elimination of these targets without damaging surrounding tissue 10 . However, microglia in the aged brain are hypo-motile 11 , burdened with lysosomal cargo 9, 12, 13 and chronically express pro-inflammatory signalling molecules 14, 15 , indicative of impaired homeostatic function. We sought to understand the molecular mechanisms governing this impairment, and to determine the consequences of restoring homeostatic microglial phagocytosis on age-related brain dysfunction.
Screen for age-related modifiers of phagocytosis
Microglia undergo marked transcriptional changes with age 16, 17 . However, the functional consequences of these molecular changes are not well understood. We aimed to identify genes that (1) modulate microglial phagocytosis, (2) are amenable to therapeutic intervention, and (3) are differentially expressed with age. To do so, we used CRISPR-Cas9 knockout screens 18, 19 to discover genetic modifiers of phagocytosis in the microglia-derived cell line BV2. Given cell-number limitations 20, 21 , screens in primary microglia are not currently feasible. Although BV2 cells do not accurately recapitulate all the features of microglia in vivo 22 , the two cell types express similar phagocytic machinery (Extended Data Fig. 1a) . Therefore, genetic modifiers of phagocytosis in BV2 cells are suitable candidates for subsequent validation in vivo. To identify potentially druggable targets, we used libraries of single-guide RNAs (sgRNAs) that target 954 genes coding for transmembrane proteins and 2,015 genes coding for known drug targets, kinases and phosphatases, with 10 sgRNAs per gene and around 3,000 negative-control sgRNAs.
Cas9-expressing BV2 cells were infected with these libraries and selected for stable sgRNA expression to obtain a pool of single-knockout cells (Fig. 1a) . We incubated the cells with pH-sensitive fluorescent latex particles and sorted phagocytic and non-phagocytic populations by fluorescence-activated cell sorting (FACS) (Extended Data Fig. 1b, c) . Next, we sequenced genomic DNA from each population, analysed the sgRNA distributions between populations (Supplementary Table 1) , and estimated the effect size and P value for each gene knockout using casTLE 23 . These screens identified 286 hits, including multiple known negative and positive regulators of phagocytosis (Supplementary  Table 2 ; Extended Data Fig. 1d-h ).
To filter this list for genes that might contribute to age-related phagocytic decline, we performed RNA sequencing (RNA-seq) analysis on hippocampal microglia from young and aged mice and compared hits from our BV2 screen to genes differentially expressed with age Article reSeArcH in primary microglia. Within the subset of genes targeted by our CRISPR-Cas9 screen, we searched for age-upregulated microglial genes for which knockout in BV2 cells promotes phagocytosis, or age-downregulated microglial genes for which knockout in BV2 cells inhibits phagocytosis (Fig. 1a) . These genes might have a functional role in age-related microglial impairment, either through increased inhibition or decreased activation of phagocytosis. CD22, a sialic acid-binding immunoglobulin-like lectin (Siglec) typically expressed on B cells 24 , was the only gene that fit these criteria (Fig. 1b) . Specifically, CD22 is significantly upregulated in aged microglia (Fig. 1c, d ), corroborating previously published datasets 16, 17 , and knocking it out in BV2 cells promotes phagocytosis ( Fig. 1e ; Extended Data Fig. 1i -k; Supplementary Video 1, 2). CD22 negatively regulates B cell receptor signalling 25 , and has been reported to modulate leukocyte phagocytosis in fish 26 . However, its role in the regulation of mammalian phagocytosis is unknown.
Other Siglecs have been shown to regulate microglial phagocytosis 27 , including suppression of amyloid-β (Aβ) clearance by CD33 in Alzheimer's disease (AD) 28 . On the basis of our RNA-seq analysis and flow cytometry profiling of primary microglia, CD22 is the only Siglec that is significantly upregulated with age in the mouse hippocampus (Supplementary Table 3 ; Extended Data Fig. 2 ). Using a quantitative flow cytometry-based assay (Extended Data Fig. 3a) , we determined that aged microglia display approximately three times more CD22 surface molecules than young microglia, comparable to the number of molecules on immature B cells (Extended Data Fig. 3b ). To assess the regional distribution of microglial CD22 expression, we performed multiplexed fluorescence RNA in situ hybridization (RNAscope) on five brain regions from young and aged mice. We probed for CD22 and TMEM119, a microglia-specific marker 29 . Whereas CD22 + TMEM119 + microglia were almost completely absent in the young brain, the aged brain contained a large proportion of these cells in every region that we assessed (Fig. 1f, g ), particularly the thalamus and cerebellum. We did not observe CD22 + puncta outside of TMEM119 + microglia, corroborating previously published RNA-seq datasets 30 showing that CD22 is expressed exclusively by microglia in the mouse CNS (Extended Data  Fig. 3c , e, f).
Sialic acid inhibits phagocytosis via CD22
CD22 is canonically expressed on B cells, where it negatively regulates B cell receptor signalling by binding sialic acid and recruiting SHP-1 or SHIP-1 via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) 31 . To search for possible signalling partners of CD22 on microglia, we re-analysed our initial CRISPR-Cas9 screen for hits related to CD22 function. Surprisingly, CMAS, a key enzyme in sialic acid synthesis, and PTPN6, which codes for SHP-1, were among the most significant hits (Fig. 2a) . Time-lapse microscopy confirmed that knocking out CMAS (CMAS-KO) or PTPN6 (PTPN6-KO), or removal of sialic acid by treatment with sialidase or 3F AX -Neu5Ac, an inhibitor of sialic acid synthesis, robustly promotes phagocytosis ( Fig. 2b, c ; Extended Data Fig. 4a-e) , phenocopying CD22 ablation. However, genetic or pharmacological inhibition of both CD22 and sialic acid simultaneously did not produce an additive effect (Fig. 2d , Extended Data Fig. 4f, g ), suggesting that sialic acid is involved in CD22-mediated inhibition of phagocytosis.
To probe CD22-sialic acid receptor-ligand interactions, we used synthetic glycopolymers functionalized with lipid tails to introduce defined glycans onto the cell surface 32 (Fig. 2e) . We decorated CMAS-KO cells, which are devoid of endogenous sialic acid, with synthetic glycopolymers bearing sialic acid linked to N-acetyllactosamine in either an α2,3-or α2,6-configuration and confirmed their incorporation into the membrane (Extended Data Fig. 4h) . Addition of α2,6-linked sialic acid, the preferred ligand of CD22
33
, but not α2,3-linked sialic acid, inhibited phagocytosis in CMAS-KO cells (Fig. 2f) . However, the Screens were performed as technical duplicates. b, RNA-seq analysis, showing differential gene expression of primary microglia from aged (20-month-old; n = 6) and young (3-month-old; n = 6) mice, overlaid with significant hits from the CRISPR-Cas9 screen of BV2 cells. Red dots represent hits that promote phagocytosis, blue dots represent hits that inhibit phagocytosis, and grey dots are knockouts that showed no effect. Dashed line represents an adjusted P value of 0.001 (Benjamini-Hochberg method). c, Reverse transcription with quantitative PCR (RT-qPCR) analysis of CD22 expression in acutely isolated primary microglia from young (2 to 3-month-old) and aged (20 to 22-month-old) mice, normalized to a housekeeping gene (Actb). Data represent fold change relative to young microglia (n = 4, ****P < 0.00005, two-sided t-test, mean ± s.e.m.). d, Flow cytometry quantification of CD22 expression in acutely isolated primary microglia from young (2 to 3-month-old) and aged (20 to 22-month-old) mice (n = 5, ***P < 0.0005, two-sided t-test, mean ± s.e.m.). MFI, mean fluorescence intensity; FMO, fluorescence minus one. e, Normalized phagocytosis (fluorescent area/confluence) monitored over 24 h, imaged every 1 h. BV2 cells were infected with a 'safe-targeting' sgRNA (control) or a sgRNA targeting CD22 (CD22-KO) (n = 6, ****P < 0.00005, two-sided t-test; mean ± s.e.m.). f, Representative images of young and aged cerebella probed for Tmem119 (green), Cd22 (red) and nuclei (DAPI, blue). Green arrows indicate TMEM119
+ microglia, and red-green arrows indicate TMEM119 + CD22 + microglia. Scale bars, 30 μm. g, Percentage of TMEM119 + microglia that co-express CD22 in multiple brain regions of young (3-month-old, brown) and aged (22-month-old, grey) mice (n = 3, *P < 0.05, ***P < 0.0005, ****P < 0.00005, two-way ANOVA with Sidak's correction, mean ± s.e.m.). Data in c-g were replicated in at least two independent experiments.
anti-phagocytic effect of α2,6-linked sialic acid was abrogated in a CMAS/CD22 double-knockout background (Fig. 2g) , demonstrating that α2,6-linked sialic acid inhibits phagocytosis in a CD22-dependent manner.
To assess inhibitory signalling downstream of CD22, we measured basal SHP-1 activity in BV2 cells and found that CD22-knockout (CD22-KO) cells express a reduced ratio of active phosphorylated SHP-1 to total SHP-1 protein, comparable to that found in CMAS-KO cells (Fig. 2h) . Furthermore, treatment with a CD22 ligand-blocking antibody (Extended Data Fig. 4i , j) decreased SHP-1 activity in a dose-dependent manner (Extended Data Fig. 4k ). Taken together, these data support a model in which CD22 binds an α2-6-sialylated ligand and promotes inhibitory SHP-1 signalling to restrain the phagocytic capacity of microglia.
CD22 blockade clears debris from the ageing brain
To assess the functional role of CD22 on aged microglia in vivo, we stereotactically co-injected myelin debris, a phagocytic substrate that accumulates in the ageing brain, with a CD22-blocking antibody or an IgG isotype control antibody into opposite brain hemispheres of the same aged mouse (Fig. 3a) . We labelled the myelin debris with a constitutively fluorescent dye to assess clearance and with a pH-sensitive dye to confirm engulfment and lysosomal trafficking within IBA1 + cells (Extended Data Fig. 5a, b) .
After 48 h, treatment with CD22 antibody robustly promoted clearance of myelin debris compared to IgG (Fig. 3b, c) . Because microglia appear to be the only cell type in the mouse CNS that express CD22 (Extended Data Fig. 3c ), this effect is likely to be microglia-specific. Notably, CD22 blockade did not influence the recruitment of microglia to the injection site relative to IgG (Extended Data Fig. 5c ) or a stab wound control (Extended Data Fig. 5d, e) , and IgG itself did not influence myelin clearance (Extended Data Fig. 5f ). Nearly all IBA1
+ cells at the injection site were TMEM119
+ regardless of treatment (Extended Data Fig. 5g, h) , suggesting that the pro-phagocytic effect of CD22 blockade is mainly mediated by resident microglia and not infiltrating peripheral macrophages 29 . We confirmed the pro-phagocytic effect of anti-CD22 treatment ex vivo using freshly isolated microglia from aged mice and pH-sensitive fluorescent latex particles (Fig. 3d) . To test this effect with an orthogonal approach, we injected labelled myelin debris into the brains of aged wild-type or Cd22 −/− mice (Fig. 3e) . We observed comparable clearance of myelin debris with genetic ablation of CD22 as with antibody-based blockade of CD22 (Fig. 3f) . Furthermore, CD22 blockade (Fig. 3g) or genetic ablation (Extended Data Fig. 5i ) had no significant effect in the young mouse CNS, where myelin debris is efficiently cleared at baseline and CD22 is minimally expressed.
Next, we evaluated the effect of CD22 blockade on microglial phagocytosis of oligomeric Aβ, a particularly neurotoxic protein aggregate that accumulates in the AD brain 34 . Compared to IgG, anti-CD22 treatment efficiently cleared injected Aβ oligomers in vivo ( Fig. 3h ; Extended Data Fig. 5j-l) . A larger percentage of residual Aβ in anti-CD22 treated hemispheres was contained in acidified lysosomes (Fig. 3i) , suggesting that CD22 blockade promotes degradation of engulfed debris. In an analogous in vivo phagocytosis assay, we found that anti-CD22 treatment promotes the clearance of extracellular α-synuclein fibrils (Extended Data Fig. 5m-o) , a pathological hallmark of Parkinson's disease. Taken together, these data suggest that CD22 is a broad negative regulator of microglial phagocytosis in the ageing brain.
CD22 blockade restores microglial homeostasis
Ageing and disease overwhelm the homeostatic function of microglia, leading to a distinctive transcriptional state 35 characterized by the downregulation of resting microglial genes and the upregulation of activated microglial genes. To assess the transcriptional effects of CD22 blockade, we implanted aged mice with osmotic pumps to continuously infuse a CD22 blocking antibody or an IgG control antibody directly into the cerebrospinal fluid for one month (Fig. 4a) . As opposed to systemic antibody administration or Cd22 −/− mice, this intervention enabled CNS-specific targeting of CD22 without B cell infiltration into the brain (Extended Data Fig. 6a ) or substantial antibody leakage 
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into the periphery (Extended Data Fig. 6b) . We labelled the respective antibodies with a fluorescent dye to assess drug distribution within the brain parenchyma (Extended Data Fig. 6c ) and target engagement with CD22 on microglia (Extended Data Fig. 6d ).
After one month of continuous infusion, we performed RNA-seq on purified microglia from the brain hemispheres of these mice contralateral to the cannulation site to minimize injury-induced confounding factors. We found very few transcriptional differences between microglia from untreated and IgG-infused mice (Extended Data Fig. 7a ). By contrast, we found 315 differentially expressed genes between microglia treated with IgG and those treated with CD22 antibody meeting a false discovery rate (FDR) cut-off of 10% (Supplementary  Table 4 ; Extended Data Fig. 7b) . We compared these genes to those that are differentially expressed between microglia from young and aged mice 36 , and between microglia from wild-type and end-stage 5xFAD AD-model mice 37 (Fig. 4b, c) . Anti-CD22 treatment promoted the upregulation of homeostatic microglial genes (for example, Tgfbr1, P2ry13, Sall1, Il10ra and Mef2a; Fig. 4d , Extended Data Figs. 7c, 8a, b) and the downregulation of activated and disease-associated microglial genes (for example, H2-K1, Tspo, Lgals3, Tnfsf13b and Ccl3; Fig. 4d , Extended Data Fig. 7d-h ), partially reversing the transcriptional hallmarks of ageing and disease. We confirmed downregulation of CCL3, a chemokine implicated in hippocampal impairment 38 , by ex vivo secretome profiling (Extended Data Fig. 8c) . Notably, CD22 blockade abrogated CCL3 secretion in the presence of oligomeric Aβ, but had no effect on basal levels.
To determine the effects of CD22 inhibition on age-related cognitive dysfunction, we assessed hippocampal-dependent learning and memory performance in aged wild-type and Cd22 −/− mice. Surprisingly, Cd22 −/− mice exhibited improved spatial memory in the forcedalternation Y-maze test ( Fig. 4e ) and improved associative memory in the contextual-fear-conditioning test (Fig. 4f ). To more specifically assess the contribution of microglial CD22 to this behavioural phenotype, we performed the same tests in aged mice infused with IgG or anti-CD22 directly into the CNS via osmotic pump. Blocking CD22 specifically in the CNS phenocopied the learning and memory improvements seen in Cd22 −/− mice ( Fig. 4g, h ), suggesting that microglial CD22 negatively and reversibly regulates cognitive function in the ageing brain. Notably, we did not observe a significant cognitive improvement in aged mice treated systemically with anti-CD22 via intraperitoneal injection, suggesting that peripheral B cells are unlikely to contribute to this effect (Extended Data Fig. 9a, b) .
These hippocampal-dependent behavioural phenotypes were accompanied by an increase in the number of hippocampal dentate granule neurons expressing c-FOS, an immediate early gene induced by neuronal activation 39 ( Fig. 4i, j) . In addition, anti-CD22 treatment promoted a modest increase in phosphorylated CREB (Extended Data Fig. 8d , e), a plasticity-related marker 40 , but did not alter hippocampal neurogenesis (Extended Data Fig. 8f ). We observed no difference in C1q deposition (Extended Data Fig. 8g ) or synaptic density, as assessed by pre-and post-synaptic markers, synaptophysin and PSD-95 (Extended Data Fig. 8h, i ).
Discussion
Here, we show that CD22 is a negative regulator of phagocytosis that is upregulated on aged microglia. CD22 mediates the anti-phagocytic effect of α2,6-linked sialic acid, and inhibition of CD22, either via antibody blockade or genetic ablation, promotes the clearance of myelin debris, Aβ oligomers and α-synuclein fibrils in vivo. Long-term CD22 blockade partially reverses the transcriptional signature of age-and disease-related microglia, increases markers of neuronal activation, and, ultimately, improves cognitive function in aged mice (Extended Data Fig. 10 ).
These findings raise several questions. First, what causes CD22 upregulation in the ageing brain? Recent studies have highlighted the importance of environmental cues in shaping microglial identity [41] [42] [43] . CD22 is enriched in a subpopulation of postnatal day 7 microglia (Extended Data Fig. 3d ) that engulf apoptotic oligodendrocytes and resemble disease-associated microglia of ageing and neurodegenerating brains 44 . Therefore, it is possible that CD22 is upregulated as a negative feedback mechanism to restrain excessive phagocytosis in response to overwhelming cellular debris in the developing brain. During ageing, this protective developmental program might be inappropriately re-activated in response to increased myelin fragmentation and protein aggregation.
How might CD22 inhibition improve cognitive function in aged mice? Our RNA-seq analysis revealed that CD22 blockade reduces the , assessed 48 h after injection (n = 8, **P < 0.005, paired two-sided t-test). d, Flow cytometry quantification of ex vivo phagocytosis of pH-sensitive beads by aged microglia pretreated with IgG or CD22 antibody (n = 6, **P < 0.005, paired two-sided t-test). e, Labelled myelin debris was stereotactically injected into the cortices of aged (12-14-month-old) wild-type or Cd22
mice. f, Clearance of myelin debris in cortices of aged wild-type (black) and Cd22 −/− (blue) mice assessed 48 h after injection (n = 4, *P < 0.05, two-sided t-test, mean ± s.e.m.). g, Clearance of myelin debris in brain hemispheres of young mice treated with IgG (black) or CD22 antibody (green), assessed 48 h after injection (n = 4, paired two-sided t-test). h, Clearance of Aβ oligomers in brain hemispheres of aged mice treated with IgG (black) or CD22 antibody (green), assessed 48 h after injection (n = 8, **P < 0.005, paired two-sided t-test). i, Percentage of residual Aβ oligomers that are CypHer5E+, indicating localization to acidified lysosomes (n = 8, **P < 0.005, paired two-sided t-test). All data were replicated in at least two independent experiments. microglial expression of various neuromodulatory pro-inflammatory molecules. Age-related impairments in perivascular glymphatic 45 and meningeal lymphatic 46 systems have been shown to affect cognitive function, and CD22-regulated phagocytosis may cooperate with these clearance pathways to control debris accumulation and local cytokine concentration in the ageing brain.
Similar to their dysfunction during normal ageing, microglia in the AD brain display signs of impaired phagocytosis, and allelic variants in microglia-specific AD-risk genes modify phagocytic function 28, [47] [48] [49] [50] . Several human RNA-seq datasets show that CD22 is upregulated in the AD brain 51 , enriched in subpopulations of microglia correlated with clinicopathological decline 52 , and, anomalously, expressed on human oligodendrocytes 53 . Furthermore, a variant in the INPP5D locus, which codes for the CD22 signalling partner SHIP-1, is associated with AD risk 54 . Determining whether CD22 function in the CNS is conserved between mice and humans will be an important step before translational studies are initiated.
In addition to AD, recent studies have found that CD22 is highly upregulated in mouse models of amyotrophic lateral sclerosis 55 , a motor neuron disease, and Niemann-Pick type C 56 , a lysosomal storage disease. Future investigations of CD22 on microglia may inform therapeutic strategies to treat or prevent these neurodegenerative diseases via restoration of homeostasis in the CNS.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-1088-4. or IgG (n = 7) and between microglia from aged (22-monthold, n = 3) and young (3-month-old, n = 3) mice 36 (b) (R = −0.47, P = 1.7 × 10 −12 ) or between microglia from 5xFAD (8.5-month-old, n = 5) and age-matched wild-type (n = 5) mice 37 (c) (R = −0.27, P = 8.5 ×10 −6 , blue line, linear regression, Spearman correlation). Genes differentially expressed (P < 0.05, two-sided t-test) in either dataset (union) are shown. d, Hierarchical clustering of gene expression changes between microglia from mice treated with CD22 antibody (n = 7) or IgG (n = 7), between microglia from aged (22-month-old, n = 3) and young (3-month-old, n = 3) mice 36 , and between microglia from 5xFAD (8.5-month-old, n = 5) and age-matched wild-type (n = 5) mice 37 . Genes differentially expressed (P < 0.05, two-tailed t-test) in all three datasets (intersection) are shown. e-h, Percentage of time spent in the novel arm of the forced alternation Y maze (e, g) or displaying freezing behaviour in a contextual-fear-conditioning test (f, h) for aged (18-month-old) wild-type and Cd22 −/− mice (e, f, n = 6) or aged (18-month-old) wild-type mice treated with IgG or CD22 antibody (g, h; independent cohorts of mice in g (n = 7 IgG, n = 9 CD22) and h (n = 7 for both groups); **P < 0.005, *P < 0.05, two-sided t-test; mean ± s.e.m.). i, Representative images of dentate gyri from mice treated with IgG or CD22 antibody, stained for PROX1 (white) and c-FOS (red). White arrows indicate c-FOS + PROX1 + active granule neurons. Scale bars, 100 μm. j, Total number of c-FOS + PROX1 + neurons in the dentate gyrus quantified across five tissue sections (n = 7, *P < 0.05, two-sided t-test; mean ± s.e.m.). Data in g-j were replicated in at least two independent experiments. . In brief, ~12 million (for 'membrane proteins' sub-library) or ~24 million (for 'drug targets, kinases, phosphatases' sub-library) BV2 cells stably expressing EF1α-Cas9-BLAST were infected with the 10 guide/gene sgRNA sub-libraries (Addgene 1000000122 and 1000000124) at a multiplicity of infection <1. Infected cells underwent puromycin selection (1.5 μg/ml) for 5 days after which point puromycin was removed and cells were resuspended in normal growth media without puromycin. After selection, sgRNA infection was confirmed by flow cytometry, which indicated that >90% of cells expressed the mCherry reporter. Sufficient sgRNA library representation was confirmed by deep sequencing after selection. Cells were cultured and maintained at 1,000× coverage for one week. Phagocytic screening prey were prepared by labelling 3 μm amino-coated polystyrene particles (Polysciences) with CypHer5E pH-dependent fluorescent dye (GE Life Sciences). Cells were switched to serum-free medium 24 h before the screen, and incubated with serum-free medium containing phagocytic prey for 1 h before sorting. For the membrane proteins screen, 12.5 million cells were sorted per replicate (>1,000× coverage) with 55.2% in the non-phagocytic gate and 11.2% in the phagocytic gate. For the drug target, kinase, phosphatase screen, 24 million cells were sorted per replicate (>1,000× coverage) with 53.1% in the non-phagocytic and 19.4% in the phagocytic gate. At the end of each screen, genomic DNA was extracted for all populations separately using a QIAGEN Blood Midi Kit, sgRNA sequences were amplified by PCR using common flanking primers, and indices and adaptors were attached to amplicons in a second PCR. Deep sequencing of sgRNA sequences on an Illumina Nextseq was used to monitor library composition. Guide composition was analysed and compared to the plasmid library and between conditions using casTLE (https://bitbucket.org/dmorgens/castle). In brief, casTLE compares each set of gene-targeting guides to the negative controls, comprising non-targeting and non-genic ('safe-targeting') sgRNAs, which have been shown to more aptly control for on-target toxicity owing to endonuclease-induced DNA damage. The enrichment of individual guides was calculated as the log ratio between phagocytic and non-phagocytic populations, and gene-level effects were calculated from ten guides targeting each gene. P values were then calculated by permutating the targeting guides as previously described 23 . Primary microglia isolation. Primary mouse microglia were isolated as previously described 20 . In brief, mice were transcardially perfused with ice-cold HBSS containing glucose and HEPES, and brains were removed into the same medium containing DNase I. On ice, brains were minced with a razor blade and a single-cell suspension was obtained by gentle Dounce homogenization. The suspension was filtered through a 100-μm strainer. Myelin was removed using magnetic myelin removal beads (Miltenyi Biotec). The remaining myelin-depleted cell suspension was stained with antibodies to distinguish microglia by flow cytometry. Previous studies have demonstrated the intense autofluorescent signal of microglia in the ageing brain, likely to be due to the accumulation of the age-related pigment, lipofuscin 14 . In order to measure the expression of proteins on aged microglia by flow cytometry, we developed a gating scheme (Extended Data Fig. 3f ) to exclude autofluorescent cells (~10% of total microglia) from our analysis. Specifically, we excluded cells with high side-scatter signal which coincided with the autofluorescent population. Whenever possible, we used fluorophores with emission spectra in far-red channels (for example, APC-Cy7). Although this technique excludes an interesting age-specific population from our analyses, it enables confident cell-surface profiling of the majority of aged microglia by flow cytometry. For RNA-seq, all microglia (including autofluorescent cells) were collected. RNA sequencing and analysis. Twenty-thousand microglia were isolated from either hemibrains or micro-dissected hippocampi as described above, and sorted into RLT Plus buffer (Qiagen) containing β-mercaptoethanol. RNA was extracted using a RNeasy Micro Plus kit (Qiagen) according the manufacturer's protocol. RNA integrity was assessed on a Bioanalyzer (Agilent), and high-quality samples were used for library preparation. cDNA synthesis and amplification was performed using the SmartSeq v.4 Ultra-low input kit (Takara), and libraries were tagmented, adaptor ligated, and indexed using the Nextera XT kit (Illumina). After normalization and pooling, libraries were sequenced on a Hiseq 4000 (Illumina) using paired-end 100-bp reads. Libraries were sequenced to a depth of >30 million reads per sample. Raw sequencing files were demultiplexed with bcl2fastq, reads were aligned using STAR, the count matrix was generated using SummarizedExperiment, and differential expression analysis was performed using DESeq2 with standard settings. Flow cytometry. Antibodies to CD11b (clone M1/70, BioLegend) and CD45 (clone 30-F11, Biolegend) were used for microglia identification (CD11b + CD45 lo ). For primary microglia immunophenotyping, the following lectins and antibodies were used: biotinylated Sambucus nigra agglutinin (SNA, Vector Labs), biotinylated Maackia amurensis agglutinins (MAA-1 and MAA-2, Vector Labs), biotinylated Erythrina crista-galli lectin (ECL, EY Labs), biotinylated wheat germ agglutinin (WGA, Vector), recombinant mouse Siglec-E (R&D Systems), recombinant mouse Siglec-F (R&D), antibodies to mouse Siglec-1 (clone REA197, Miltenyi Biotec), CD22 (clone OX-97, Biolegend), Siglec-E (clone M1304A01, Biolegend), Siglec-F (clone ES22-10D8, Miltenyi Biotec), Siglec-G (clone SH1, BD Biosciences), Siglec-H (clone 551, Biolegend) and CD33 (clone 9A11, eBioscience). For immunostaining, cells were passed through a 100-μm strainer, blocked for 10 min on ice with mouse Fc-blocking reagent (BD Biosciences), and stained for 30 min on ice in PBS supplemented with 0.5% bovine serum albumin. When biotinylated antibodies or lectins were used, cells were stained with APC-Cy7-conjugated streptavidin (Biolegend) for 15 min on ice following primary stain. When recombinant Siglecs were used, they were precomplexed with APC-Cy7-conjugated anti-human IgG Fc (Biolegend) on ice at 10 μg/ml each. The complex was used at a final staining concentration of 5 μg/ml. Live cells were identified using Sytox Blue viability dye. Flow cytometry analysis was performed on a BD LSRFortessa and sorting was performed on a BD FACSAria III. Data were analysed using FlowJo software (TreeStar). Quantitative flow cytometry. Primary microglia from young and aged mice were isolated as described above. For the same mice, peripheral blood was collected with EDTA anticoagulant by terminal intracardial bleeding. Whole blood was mixed 1:1 with PBS and layered over Ficoll-Paque Plus (GE), spun at 400g for 30 min with no break, and the peripheral blood mononuclear cell fraction was collected. Microglia and peripheral blood cells were stained with immunophenotyping antibodies as well as PE-conjugated anti-CD22 (Ox97, Biolegend). Quantibrite-PE (BD) beads were resuspended in FACS buffer and analysed on a BD LSRFortessa. Using the same laser powers and detector voltages, peripheral blood and microglia samples were analysed for CD22 expression. A standard curve was constructed to correlate PE intensity with number of PE molecules per Quantibrite bead. Finally, CD22 molecule numbers on microglia and peripheral blood cells were calculated by interpolation. RT-qPCR. Microglia were isolated by FACS and RNA was extracted as described above. cDNA synthesis and amplification were performed with a SMART-seq V4 Ultra-Low Input RNA Kit (Clontech). Samples were diluted and mixed with SYBR green master mix before loading as technical triplicates for qPCR on a LightCycler 480 (Roche). ΔΔC T values normalized to Actb were used to assess relative gene expression between samples. The following validated primer pairs for mouse CD22 were used: 5′-CCACTCCTCAGGCCAGAAACT-3′ (forward) and 5′-TGCCGATGGTCTCTGGACTG-3′ (reverse). In vitro phagocytosis assay. For in vitro phagocytosis assays, BV2 cells were split into a 24-well plate 24 h before feeding at a density of 50,000 cells per well in serumfree medium. Following specific treatments, wells were washed twice with PBS and fed pHrodo red-labelled 3-μm amino-coated polystyrene particles (Polysciences) at a ratio of 10 particles per cell. Four phase and red-fluorescent images per well were acquired every hour for 24 h using the Incucyte S3 live-cell analysis system (Essen Bioscience). For each time point, normalized phagocytosis was calculated using the following formula: (red object area)/(phase confluence). To combine data from independent experiments, we calculated phagocytosis relative to control by setting phagocytosis at zero hours in the control condition to 0, and this value at 24 h to 1. Technical triplicates for each experiment were averaged, and the average of independent experiments was reported. RNAScope in situ hybridization. RNA in situ hybridization was performed on fresh frozen brain tissue using the Multiplex Fluorescence v.2 kit (Advanced Cell Diagnostics) according to the manufacturer's protocol. Probes for CD22 and TMEM119 were commercially available from the manufacturer. Lentivirus production and infection. HEK293T cells were transfected with packaging plasmids and sgRNA-containing plasmids. Supernatant was harvested at 48 h and 72 h and concentrated with Lenti-X solution (Clontech). BV2 cells stably expressing Cas9 endonuclease under blasticidin (1 μg/ml) selection were spin infected with lentivirus containing sgRNA plasmids with puromycin Article reSeArcH resistance cassettes. Puromycin selection (1.5 μg/ml) was started 48 h after infection and maintained for 7-14 days. Antibiotic selection was subsequently removed for expansion and freezing. CMAS-KO and CD22-KO BV2 cells were sub-cloned by single-cell sorting to obtain a monoclonal knockout population. Other single-knockout cell lines were assayed as a polyclonal population. Sialidase expression. Sialidase from Vibrio cholerae was prepared as previously described 57 . In brief, Escherichia coli C600 transformed with the pCVD364 vector containing the V. cholerae sialidase gene were grown in 2xYT media supplemented with ampicillin (100 μg/ml) for 12 h at 37 °C. Cells were collected by centrifugation at 4,500g for 10 min. The pellet was resuspended in osmotic shock buffer (20% sucrose, 1 mM EDTA, 30 mM Tris-HCl, pH 8), incubated for 10 min at room temperature, then spun at 13,000g for 10 min. The pellet was resuspended in ice cold ddH2O, incubated at 4 °C for 10 min, and then spun at 13,000g. The supernatant was concentrated using a tangential flow filtration system (Pall Corporation). The concentrate was loaded onto a HiTrap Q HP anion exchange column (GE Healthcare Life Sciences) and eluted using a gradient of NaCl in 20 mM Tris, pH 7.6. Fractions containing sialidase were assessed by SDS-PAGE and pooled. Endotoxins were removed using a high capacity endotoxin removal kit (Thermo Fisher Scientific). Sialic acid inhibition. For sialidase treatment, cells were incubated with 400 nM V. cholerae sialidase for 1 h at 37 °C in serum-free DMEM before phagocytosis. 3F AX -Neu5Ac (R&D Systems) was used as previously described 58 . In brief, the inhibitor was used at a concentration of 32 μM, serially diluted in DMSO, and used at a final concentration of 0.1% DMSO in DMEM. 3F AX -Neu5Ac was added with serum treatments for 48 h before phagocytosis assays, and replaced in the feeding medium. Glycopolymer decoration. Aminooxy glycan-conjugated polymers were based on a poly(methyl vinyl ketone) backbone coupled to a dipalmitoylphosphatidylethanolamine lipid anchor. Glycopolymers were conjugated at 70-85% of ketone sites to either Neu5Ac-α2,3-LacNAc or Neu5Ac-α2,6-LacNAc through oxime chemistry. Cells were decorated with aminooxy glycan-conjugated polymers as previously described 32 . In brief, cells were harvested and resuspended in PBS at 10 7 cells/ml. Labelling was carried out by incubating the cell suspension with 1 μM polymer for 30 min at room temperature with constant gentle agitation. Cells were washed with PBS and split into a 24-well plate at 50,000 cells per well for subsequent phagocytosis assays. Western blot. Protein lysates were prepared by incubating cell pellets on ice in Pierce IP Lysis Buffer or RIPA Lysis Buffer with cOmplete protease inhibitor cocktail (Thermo Fisher Scientific) and spun at 13,000g for 10 min. The supernatant was collected and protein concentration was measured with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). An aliquot containing 5-20 μg of protein from each sample was mixed with 4× loading buffer (Thermo Fisher Scientific) and boiled for 5 min at 95 °C before being subjected to SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad). The membrane was first blocked with Odyssey Blocking Buffer (LI-COR) and stained overnight at 4 °C with primary antibodies at the designated concentrations: mouse anti-α-tubulin (1:10,000, T9026, Sigma), rabbit anti-pSHP-1 (1:5,000, D11G5, Cell Signaling), rabbit antiSall1 (1:1,000, ab31526, Abcam). The membrane was washed, stained with IRDye conjugated secondary antibodies (1:15,000, LI-COR) and imaged on the Odyssey CLx (LI-COR). The membrane was stripped by incubation with ReBlot Plus Strong Antibody Stripping Solution (Millipore) for 15 min before blocking, staining with anti-SHP-1 (1:10,000, C14H6, Cell Signaling) then an IRDye conjugated secondary antibody, and reimaged as described. Images were analysed for band intensities with the ImageStudio software (LI-COR). Antibody-mediated inhibition assay. Wild-type BV2 cells were incubated in serum-free DMEM containing varying concentrations of a monoclonal anti-CD22 antibody (Cy34, BioXCell) from 20 μg/ml to 0 μg /ml for 8 h at 37 °C. The p-SHP-1:total SHP-1 ratio, indicative of signalling activity downstream of CD22, was determined by blotting with phosphoantibodies as described above. Ligand-binding assay. Recombinant mouse CD22-human Fc fusion protein (R&D) was pre-complexed to an AF647-conjugated anti-human IgG secondary antibody on ice for 30 min at equal concentrations (10 μg/ml). The complex was then incubated with various concentrations of a mouse monoclonal anti-CD22 antibody (Cy34, BioXCell) or a mouse IgG1 isotype control antibody (MOPC21, BioXCell) on ice for 30 min. Next, the antibody-treated complexes were incubated with wild-type or sialidase treated BV2 cells for 30 min on ice. The cells were washed and rCD22 binding was assessed by flow cytometry on a BD Accuri C6. Antibody-internalization assay. Wild-type BV2 cells were split into a 24-well plate 24 h before antibody treatment at a density of 50,000 cells per well. Cells were treated with rat anti-mouse CD16/CD32 Fc Blocker (2.4G2, BD) then incubated with the following antibodies at 1 μg/ml mouse IgG1 isotype control antibody (MOPC21, BioXCell), mouse anti-CD22 (Cy34, BioXCell) and rat anti-CD22 (OX-96, Bio-Rad). All antibodies were pre-labelled with Incucyte FabFluor-pH Red (Essen Bioscience) according to the manufacturer's protocol. Nine phase and red fluorescent images per well were acquired every hour for 24 h using the Incucyte S3 live-cell analysis system (Essen Bioscience). For each time point, we calculated antibody internalization using the following formula: (Red object area/Phase confluence). Technical triplicates for each experiment were averaged and reported. Immunohistochemistry. Mice were euthanized with 2.5% (v/v) Avertin and transcardially perfused with ice-cold HBSS containing glucose and HEPES, or with 4% PFA. Hemibrains were post-fixed in 4% PFA at 4 °C overnight before preservation in 30% sucrose in PBS. Hemibrains were sectioned into 40-μm coronal slices on a microtome and stored in cryoprotective solution at −20 °C. Free-floating sections were permeabilized, blocked, and stained overnight at 4 °C with the following primary antibodies at the designated concentrations: goat anti-IBA1 (1:500, ab5076, Abcam), goat anti-PROX1 (1:500, AF2727, R&D), rabbit anti-c-Fos (1:400, 9F6, Cell Signaling), rabbit anti-Aβ (1:200, D54D2, Cell Signaling), rabbit anti-α-synuclein (1:200, MJFR1, Abcam), rabbit anti-p-CREB (1:500, 06-519, Millipore), rabbit anti-synaptophysin (1:500, D8F6H, Cell Signaling), rabbit anti-PSD95 (1:500, D27E11, Cell Signaling), rabbit anti-C1q (1:1200, ab182451, Abcam), goat anti-doublecortin (1:500, SC8066, Santa Cruz Biotech), rabbit anti-CD19 (1:500, D4V4B, Cell Signaling) and rabbit anti-TMEM119 (1:100, 28-3, Abcam). Sections were washed, stained with Alexa Fluor-conjugated secondary antibodies (1:250), mounted and set under a coverslip before imaging on a confocal laser-scanning microscope (Zeiss LSM880). Thioflavin S staining was performed after secondary antibody staining. In brief, sections were stained in a 0.1% (w/v) solution for 5 min, followed by 3 washes in 50% EtOH, and a 30 min rehydration in diH2O before mounting. All analyses were performed by a blinded observer. Preparation of fluorescent phagocytic material. Purified CNS myelin was isolated as previously described 59 . In brief, mice were euthanized and their brains homogenized. Crude brain homogenate was subjected to a series of sucrose gradients under ultracentrifugation followed by osmotic shocks in hypotonic buffers to remove myelin sheaths from severed axons. Aβ oligomers were prepared as previously described 60 . In brief, Aβ 1-42 (Anaspec) was treated with hexafluoroisopropanol to achieve a monomeric solution. Oligomerization was induced by diluting a 5 mM monomeric Aβ DMSO stock to 200 μM in ice-cold PBS and incubated overnight at 4 °C. Pre-formed α-synuclein fibrils were prepared as previously described 61 . Phagocytic material was conjugated to fluorescent dyes as previously described 21 . For double-labelled myelin, 50 mg/ml myelin prep was incubated with equimolar concentrations of AlexaFluor555 NHS ester and CypHer5E NHS ester in PBS with 0.1 M sodium bicarbonate for 45 min at room temperature. Myelin was washed 4 times with PBS and centrifugation to remove free dye. For Aβ and α-synuclein, 100 μl of the 200 μM protein aggregates were incubated with 4 μl CypHer5E NHS ester in PBS with 0.1 M sodium bicarbonate for 30 min at room temperature. Free dye was removed using BioSpin Micro P-6 desalting columns (BioRad). In vivo phagocytosis assay. CypHer5E and AlexaFluor555 double-labelled myelin (25 mg/ml), CypHer5E-labelled Aβ oligomers (1 mg/ml), or CypHer5E-labelled α-synuclein fibrils (1 mg/ml) were mixed with a mouse IgG1 isotype control antibody (MOPC21, BioXCell, 1 mg/ml) or anti-CD22 (Cy34, BioXCell, 1 mg/ml) and injected into opposite hemispheres of aged mice using a stereotaxic apparatus (Kopf instruments). Mice were anaesthetized using isofluorane, their skulls were exposed and a hole was drilled at the injection site using aseptic technique. One microlitre of the antibody-phagocytic target material mixture was injected at ±2 mm lateral, 0 mm anterior-posterior, and −1.5 mm deep relative to the intersection of the coronal and sagittal suture (bregma) at a rate of 200 nl/min. The needle was left in place for an additional 3 min to allow for diffusion, then slowly withdrawn. Mice received post-surgical buprenorphine and baytril for pain and infection prevention, respectively. After 48 h, mice were anaesthetized and transcardially perfused with 4% PFA. The entire injection site was sectioned, stained, and imaged as described above, and 6-8 consecutive sections, spaced 40 μm apart, were quantified to assess total target clearance over the entire area of the injection site. Sections at the margins of the injection site without noticeable IBA1+ microgliosis (which takes >48 h to resolve and is not influenced by treatment) were excluded. All analyses were performed by a blinded observer. Ex vivo microglial phagocytosis assay. Whole-brain myelin-depleted single-cell suspensions were prepared as described above. Next, a rough estimation of microglia counts from each brain was determined by strictly gating a volume-designated aliquot of the suspensions by forward scatter/side scatter on a flow cytometer (BD Accuri C6). Each suspension was adjusted to contain equal microglia per unit volume. Then, single-cell brain suspensions were treated accordingly for 1 h in serum-free DMEM-F12 at 37 °C with periodic agitation. Treatments were washed out and cells were resuspended in FACS buffer containing pHrodo-or CypHer5E-conjugated particles at a ratio of 50 particles per microglia. The cell-particle mixture was incubated for 1-2 h at 37 °C with periodic agitation. Phagocytosis was stopped by transferring the suspensions to ice, where the cells were stained with antibodies to distinguish microglia. Microglial phagocytosis was assessed by flow cytometry by pre-gating live CD11b +
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lo cells and assessing pH-dependent particle fluorescence within this population. The eating gate was determined using an unfed control, and confirmed by sorting an aliquot of the sample into non-eating and eating populations by FACS followed by microscopic assessment. Osmotic pump intracerebroventricular delivery of anti-CD22. A monoclonal anti-CD22 antibody (Cy34, BioXCell, 1 mg/ml) or mouse IgG1 isotype control antibody (MOPC21, BioXCell, 1 mg/ml) was conjugated to Alexa Fluor 647 (ThermoFisher) using NHS chemistry at a dye:protein molar ratio of 4. Free dye was removed and buffer was exchanged with artificial CSF (Tocris) using 40 kD MWCO Zeba spin desalting columns (ThermoFisher). The labelled antibodies were loaded into 200-μl osmotic pumps (Alzet/Durect) with a 28-day infusion rate of 0.25 μl per h. An infusion rate was chosen to maintain a steady state concentration of 10 μg/ml, a dose shown to promote phagocytosis with this particular antibody ex vivo. Osmotic pumps were connected to a cannula (Brain infusion kit III, Alzet) inserted at +1 mm lateral, −0.3 mm anterior-posterior, and −3mm deep relative to bregma in order to target the right lateral ventricle. The pump was placed subcutaneously and mice received post-surgical buprenorphine and Baytril. Mice were randomized to either the IgG or the anti-CD22 group. Quantification of antibody leakage into the periphery following intracerebroventricular administration. One milligram of CD22 antibody was incubated with 30× molar ratio of trans-cyclooctene (TCO) NHS ester (Click Chemistry Tools) overnight at 4 °C before being quenched with 1 M Tris pH 8.0 and desalted (Zeba, 40 kDa MWCO, Thermo). Mice were administered unlabelled or TCOlabelled CD22 antibody via osmotic pump intracerebroventricularly as detailed above, or with equimolar amounts intravenously (retro-orbital) or intraperitoneally. Seven days later, blood was collected with EDTA anticoagulant by terminal intracardial bleeding. EDTA-plasma was isolated by centrifugation at 1,000g for 15 min at 4 °C before aliquoting, flash freezing, and storage at −80 °C. Protein concentrations of plasma samples and unlabelled and TCO-labelled CD22 antibodies were measured with a BCA Protein Assay Kit (Pierce). Plasma (75 μg) was aliquoted, denatured in 1% SDS, and incubated for 90 min in the dark at room temperature with 6 μM SiR-tetrazine (Spirochrome) for subsequent click chemistry detection by in-gel fluorescence. Decreasing amounts (10×) of unlabelled and TCO-labelled CD22 antibody-from 1 μg to 0.1 ng-were processed similarly as a fluorescence standard. A 4× stock solution of NuPAGE LDS (Thermo) was added to each sample before heating at 95 °C for 5 min. Proteins were briefly spun and separated by electrophoresis in 12% Bis-Tris polyacrylamide gels (Invitrogen). Gels were washed twice in distilled water for 15 min before SiR imaging in the 700-nm channel of an Odyssey CLx (LI-COR). To ensure accurate protein loading, gels were incubated with GelCode Blue Stain Reagent (Thermo) overnight before destaining in distilled water for at least 3 h and imaged in the 800-nm channel of an Odyssey CLx (LI-COR). CD22 fluorescence signals were quantified in accompanying Image Studio software (LI-COR). Behavioural assays. The forced alternation Y-maze was performed as previously described with minor alterations 62 . In brief, the test consisted of a 5-min training trial followed by a 5-min retrieval trail, with a 1-h inter-trial interval. For the training trial, one arm of the Y maze was blocked off and mice were allowed to explore the two open arms. One hour later, the mouse was again placed in the Y maze with all three arms open and a black and white pattern placed at the end of the novel arm. Between mice and trials, the maze was wiped with ethanol to remove odour cues. For analysis, video was analysed by a blinded observer and both number of arm entries and time spent in each arm were quantified. Mice with less than two arm entries in the first minute of the retrieval trial were excluded from the analysis.
The fear-conditioning paradigm was performed as previously described 63 . In brief, mice were trained to associate cage context or an audiovisual cue with an aversive stimulus (foot shock). The test was administered over two days. On day 1, mice were placed in a cage and exposed to two periods of 30 s of paired cue light and 1,000-Hz tone followed by a 2-s foot shock (0.6 mA), with a 180-s interval. On day 2, mice were subjected to two trials. In the first trial assessing contextual memory, mice were re-exposed to the same cage context, and freezing behaviour was measured during minute 1-3 using a FreezeScan tracking system (Cleversys). In the second trial measuring cued memory, mice were placed in a novel context and exposed to the same cue light and tone from day 1 after 2 min of exploration. Freezing behaviour was measured for 1-3 min following the cue. No significant differences in cued fear conditioning were observed between groups, consistent with previous rejuvenation studies from our laboratory 64 . Assessment of the cognitive effects of systemically administered anti-CD22. Aged (18-month-old) mice were intraperitoneally injected with 300 μg anti-CD22 (Cy34, BioXCell) or mouse IgG1 isotype control (MOPC21, BioXCell) twice weekly for one month, followed by cognitive assessment using the forced alternation Y-maze and contextual-fear-conditioning paradigms described above. Gene Ontology analysis. For Gene Ontology analysis of CRISPR-Cas9 screen hits, Panther was used to assess statistical overrepresentation of hits in the Reactome pathway database given a reference list containing all genes targeted by the sgRNA library. For analysis of RNA-seq data, Enrichr was used to assess enrichment of significantly up-or downregulated genes in KEGG, BioCarta, WikiPathways, and Reactome databases. Pre-ranked gene set enrichment analysis (GSEA) was performed with GSEA software v.3 (Broad Institute) with default settings and signed log-normalized P values as a ranking metric. Ex vivo microglia secretome profiling. Microglia from aged (20-24-month-old) mice were isolated as described above, with minor modifications. Namely, following myelin depletion, cells were incubated with CD11b-positive enrichment beads (Miltenyi), isolated by magnetic selection using LS-columns, and plated at 30,000 cells per well of a 96-well plate. Microglia were maintained in serum-free defined medium as previously described 21 , and treated with either IgG (MOPC21, BioXCell, 20 μg/ml) or anti-CD22 (Cy34, BioXCell, 20 μg/ml) in the presence or absence of Aβ oligomers (5 μM) for 8 h. Following incubation, supernatant was collected, spun down to remove cells, and flash frozen on dry ice. A bead-based immunoassay for mouse cytokines and chemokines (Eve Technologies) was used for protein detection. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Methodology Sample preparation
For immunostaining, cells were passed through a 100 micron strainer, blocked for 10 minutes on ice with mouse Fc-blocking reagent (BD), and stained for 30 minutes on ice in PBS supplemented with 0.5% bovine serum albumin. Cell population abundance For immunophenotyping, at least 5,000 cells of the population of interest were analyzed.
For sorting for RNA-seq, at least 10,000 microglia were collected.
Gating strategy
Positive and negative gates were set using fluorescence minus one (FMO) background intensity controls. Fluorophores were chosen to minimize spectral overlap.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
